Press Releases

InVivo Therapeutics Requests Humanitarian Use Device Designation with FDA

Published: December 14, 2012

CAMBRIDGE, Mass. (December 14, 2012) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the Company has filed a request with the U.S. Food and Drug Administration (FDA) for Humanitarian Use Device (HUD) designation for its biopolymer scaffolding product. InVivo is currently working with the FDA on the final steps to seek approval to begin a clinical trial of the scaffolding in acute SCI in early 2013. Devices eligible for HUD designation are developed to treat rare diseases or conditions. InVivo has requested […]

View Article
InVivo Therapeutics Reports Third Quarter 2012 Financial Results, Provides Business Update

Published: November 14, 2012

CAMBRIDGE, Mass. (November 14, 2012) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today reported the financial results for the three and nine months ended September 30, 2012 and provided a business update. InVivo has pioneered a new treatment platform utilizing a variety of biocompatible polymer-based devices to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving functional recovery and prognosis after a traumatic spinal cord injury. Today there is no effective treatment for the spinal cord […]

View Article
InVivo Therapeutics to Present at Lazard Capital Markets 9th Annual Healthcare Conference

Published: November 12, 2012

CAMBRIDGE, Mass. (November 12, 2012) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that CEO Frank Reynolds will present recent updates and meet one-on-one with potential investors during the Lazard Capital Markets 9th Annual Healthcare Conference November 13-14 at The Pierre Hotel in New York City. Reynolds will present at 3:00pm ET on Wednesday, November 14; the presentation will be simultaneously webcast at http://wsw.com/webcast/lz13/nviv/. During his talk, Reynolds will provide an overview of InVivo’s biomaterial technologies that are intended to provide structural support […]

View Article
Dr. Alex Aimetti of InVivo Therapeutics to Speak at Working 2 Walk Spinal Cord Injury Symposium

Published: October 31, 2012

CAMBRIDGE, Mass. (October 31, 2012) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced the Company’s sponsorship of the 7th annual Working 2 Walk Science & Advocacy Symposium that will take place November 1-3, 2012 in Irvine, CA. Working 2 Walk is an annual event held by Unite 2 Fight Paralysis to bring together spinal cord injury research scientists, practitioners, investors and consumers for a lively discussion of current research and strategies that will accelerate progress toward cures for paralysis. Unite 2 Fight Paralysis […]

View Article
InVivo Therapeutics Releases Letter to Shareholders

Published: October 12, 2012

InVivo Therapeutics Releases Letter to Shareholders | Invivo Therapeutics Cambridge, Mass. (October 12, 2012) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma, today released a letter to Shareholders. To Our Shareholders and Potential Shareholders: InVivo has been making excellent progress in the past months and we are firing on all cylinders.  I wanted to use this letter as a forum to provide an important update on how we are using InVivo’s resources to create and capture shareholder value.  We expect the next six months to mark a […]

View Article
InVivo Therapeutics Awarded $2 Million Loan from MassDevelopment

Published: October 9, 2012

Will Fund Expansion of Manufacturing and Research Capabilities at New Facility Cambridge and Boston, Mass. (October 9 2012) – InVivo Therapeutics Holdings Corp. (NVIV), and MassDevelopment announced today that MassDevelopment has awarded InVivo Therapeutics a $2 million loan from its Emerging Technology Fund to help fund the commercialization of InVivo’s groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions. InVivo will use the proceeds from this low cost, seven year term loan for general working capital purposes and to purchase equipment for the expansion of manufacturing and research capabilities at its new facility in Cambridge […]

View Article
InVivo Therapeutics Names Veteran Biomaterials Expert Bill D’Agostino as Senior Director of Manufacturing & Engineering

Published: September 28, 2012

CAMBRIDGE, Mass. (September 28, 2012) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma, today announced the appointment of Bill D’Agostino as Senior Director of Manufacturing & Engineering. An executive leader focused on rapid market growth, Mr. D’Agostino joins InVivo following fifteen years at Covidien and, most recently, seven years at Angiotech Pharmaceuticals as Vice President, Engineering. In his career to date, Mr. D’Agostino has launched more than 100 new polymer products including families of biodegradable sutures. Mr. D’Agostino is a seasoned professional in medical devices and pharmaceutical […]

View Article
InVivo to Present at 2012 Aegis Healthcare Conference

Published: September 27, 2012

CAMBRIDGE, Mass. (September 27, 2012) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma, today announced that CEO Frank Reynolds is scheduled to present at the 2012 Aegis Healthcare Conference to be held September 27-29, 2012 at The Wynn, Las Vegas. The Company’s presentation will be on Friday, September 28th at 9:30 a.m. PDT (12:30 pm EDT). About the Neuro-Spinal Scaffold Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and acts as a physical substrate for nerve […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.